Perspective Historical Income Statement

CATX Stock

4.35 0.23 5.58%

Historical analysis of Perspective Therapeutics income statement accounts such as Total Revenue of 1.4 M, Gross Profit of 1.3 M or Other Operating Expenses of 44.5 M can show how well Perspective Therapeutics performed in making a profits. Evaluating Perspective Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Perspective Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Perspective Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Perspective Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Perspective Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.

About Perspective Income Statement Analysis

Perspective Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Perspective Therapeutics shareholders. The income statement also shows Perspective investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Perspective Therapeutics Income Statement Chart

At this time, Perspective Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 44.5 M in 2024, whereas Total Revenue is likely to drop slightly above 1.4 M in 2024.

Ebit Selling And Marketing Expenses Net Income Applicable To Common Shares

Net Income Applicable To Common Shares

The net income that remains after preferred dividends have been deducted, available to common shareholders.

Most accounts from Perspective Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Perspective Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Perspective Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Perspective Stock please use our How to Invest in Perspective Therapeutics guide.At this time, Perspective Therapeutics' Depreciation And Amortization is fairly stable compared to the past year. Other Operating Expenses is likely to rise to about 44.5 M in 2024, whereas Total Revenue is likely to drop slightly above 1.4 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	18.2M	17.4M	42.4M	44.5M
Cost Of Revenue	6.2M	5.5M	4.9M	4.2M

Total Operating Expenses Cost Of Revenue

Perspective Therapeutics income statement Correlations

	Depreciation And Amortization	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Interest Expense	Selling General Administrative	Selling And Marketing Expenses	Research Development	Net Interest Income	Interest Income	Net Income From Continuing Ops	Reconciled Depreciation	Tax Provision
Depreciation And Amortization		-0.78	-0.57	0.41	-0.53	-0.53	-0.51	-0.26	0.42	-0.53	0.2	-0.54	-0.44	0.08	0.41	-0.73	0.54	0.48	0.48	-0.4	0.45	0.55
Total Revenue	-0.78		0.77	-0.44	0.6	0.6	0.59	0.47	-0.43	0.6	-0.2	0.61	0.52	0.04	-0.41	0.75	-0.59	-0.54	-0.53	0.44	-0.47	-0.61
Gross Profit	-0.57	0.77		0.11	0.06	0.05	0.04	0.24	0.13	0.06	0.02	0.06	-0.02	0.08	0.13	0.62	-0.02	-0.12	-0.11	0.09	-0.04	-0.07
Other Operating Expenses	0.41	-0.44	0.11		-0.98	-0.98	-0.98	0.05	1.0	-0.98	0.51	-0.98	-0.86	0.17	0.99	-0.32	0.97	0.92	0.92	-0.86	0.94	0.88
Operating Income	-0.53	0.6	0.06	-0.98		1.0	1.0	0.05	-0.98	1.0	-0.5	1.0	0.87	-0.15	-0.97	0.43	-0.98	-0.93	-0.93	0.86	-0.93	-0.93
Ebit	-0.53	0.6	0.05	-0.98	1.0		1.0	0.06	-0.98	1.0	-0.49	1.0	0.87	-0.14	-0.97	0.43	-0.98	-0.93	-0.93	0.86	-0.93	-0.93
Ebitda	-0.51	0.59	0.04	-0.98	1.0	1.0		0.05	-0.98	1.0	-0.49	1.0	0.87	-0.14	-0.97	0.41	-0.98	-0.93	-0.93	0.86	-0.94	-0.93
Cost Of Revenue	-0.26	0.47	0.24	0.05	0.05	0.06	0.05		0.04	0.06	0.24	0.06	0.09	0.16	0.04	0.02	-0.06	0.06	0.06	-0.13	0.09	-0.04
Total Operating Expenses	0.42	-0.43	0.13	1.0	-0.98	-0.98	-0.98	0.04		-0.97	0.49	-0.97	-0.86	0.18	1.0	-0.31	0.97	0.9	0.9	-0.83	0.92	0.89
Income Before Tax	-0.53	0.6	0.06	-0.98	1.0	1.0	1.0	0.06	-0.97		-0.47	1.0	0.86	-0.14	-0.97	0.43	-0.98	-0.93	-0.93	0.86	-0.93	-0.93
Total Other Income Expense Net	0.2	-0.2	0.02	0.51	-0.5	-0.49	-0.49	0.24	0.49	-0.47		-0.47	-0.76	0.37	0.48	-0.31	0.5	0.53	0.53	-0.51	0.53	0.47
Net Income	-0.54	0.61	0.06	-0.98	1.0	1.0	1.0	0.06	-0.97	1.0	-0.47		0.87	-0.13	-0.96	0.46	-0.99	-0.92	-0.92	0.84	-0.92	-0.94
Income Tax Expense	-0.44	0.52	-0.02	-0.86	0.87	0.87	0.87	0.09	-0.86	0.86	-0.76	0.87		-0.13	-0.84	0.45	-0.9	-0.75	-0.75	0.66	-0.76	-0.86
Interest Expense	0.08	0.04	0.08	0.17	-0.15	-0.14	-0.14	0.16	0.18	-0.14	0.37	-0.13	-0.13		0.18	-0.02	0.13	0.22	0.22	-0.25	0.23	0.09
Selling General Administrative	0.41	-0.41	0.13	0.99	-0.97	-0.97	-0.97	0.04	1.0	-0.97	0.48	-0.96	-0.84	0.18		-0.26	0.94	0.91	0.91	-0.86	0.94	0.86
Selling And Marketing Expenses	-0.73	0.75	0.62	-0.32	0.43	0.43	0.41	0.02	-0.31	0.43	-0.31	0.46	0.45	-0.02	-0.26		-0.52	-0.32	-0.32	0.19	-0.27	-0.56
Research Development	0.54	-0.59	-0.02	0.97	-0.98	-0.98	-0.98	-0.06	0.97	-0.98	0.5	-0.99	-0.9	0.13	0.94	-0.52		0.86	0.86	-0.77	0.87	0.94
Net Interest Income	0.48	-0.54	-0.12	0.92	-0.93	-0.93	-0.93	0.06	0.9	-0.93	0.53	-0.92	-0.75	0.22	0.91	-0.32	0.86		1.0	-0.98	1.0	0.79
Interest Income	0.48	-0.53	-0.11	0.92	-0.93	-0.93	-0.93	0.06	0.9	-0.93	0.53	-0.92	-0.75	0.22	0.91	-0.32	0.86	1.0		-0.98	1.0	0.79
Net Income From Continuing Ops	-0.4	0.44	0.09	-0.86	0.86	0.86	0.86	-0.13	-0.83	0.86	-0.51	0.84	0.66	-0.25	-0.86	0.19	-0.77	-0.98	-0.98		-0.98	-0.7
Reconciled Depreciation	0.45	-0.47	-0.04	0.94	-0.93	-0.93	-0.94	0.09	0.92	-0.93	0.53	-0.92	-0.76	0.23	0.94	-0.27	0.87	1.0	1.0	-0.98		0.79
Tax Provision	0.55	-0.61	-0.07	0.88	-0.93	-0.93	-0.93	-0.04	0.89	-0.93	0.47	-0.94	-0.86	0.09	0.86	-0.56	0.94	0.79	0.79	-0.7	0.79

Click cells to compare fundamentals

Perspective Therapeutics Account Relationship Matchups

Perspective Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	147K	9K	248K	344K	981K	1.0M
Total Revenue	9.7M	10.1M	10.8M	7.1M	1.4M	1.4M
Gross Profit	5.1M	5.1M	4.6M	1.6M	1.4M	1.3M
Other Operating Expenses	13.2M	13.5M	18.2M	22.9M	42.4M	44.5M
Operating Income	(3.5M)	(3.4M)	(7.4M)	(15.2M)	(40.9M)	(38.9M)
Ebit	(3.6M)	(3.4M)	(7.4M)	(15.2M)	(40.9M)	(38.9M)
Ebitda	(3.5M)	(3.4M)	(7.1M)	(14.8M)	(40.0M)	(38.0M)
Cost Of Revenue	4.6M	4.9M	6.2M	5.5M	4.9M	4.2M
Total Operating Expenses	8.6M	8.6M	18.2M	17.4M	42.4M	44.5M
Income Before Tax	(3.4M)	(3.4M)	(7.3M)	(14.7M)	(40.1M)	(38.1M)
Total Other Income Expense Net	30K	50K	119K	512K	835K	876.8K
Net Income	(3.3M)	(3.2M)	(7.3M)	(14.7M)	(46.5M)	(44.2M)
Income Tax Expense	(294K)	(177K)	(199K)	(119K)	(2.7M)	(2.5M)
Interest Expense	29K	30K	50K	119K	84K	89.8K
Selling General Administrative	4.6M	4.7M	9.4M	10.9M	21.0M	22.0M
Selling And Marketing Expenses	3.0M	2.4M	2.8M	3.2M	97K	92.2K
Research Development	1.1M	1.4M	2.6M	2.6M	21.3M	22.4M
Net Interest Income	30K	59K	119K	850K	977.5K	1.0M
Interest Income	30K	59K	119K	934K	1.1M	1.1M
Net Income From Continuing Ops	(3.4M)	(3.4M)	(7.3M)	(37.5M)	(33.7M)	(32.0M)
Reconciled Depreciation	147K	149K	248K	946K	1.1M	1.1M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Perspective Stock Analysis

When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Perspective Historical Income Statement

About Perspective Income Statement Analysis

Perspective Therapeutics Income Statement Chart

Net Income Applicable To Common Shares

Perspective Therapeutics income statement Correlations

Perspective Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Perspective Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Perspective Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit

Research Development	- 0.99	Net Income
Reconciled Depreciation	- 0.98	Net Income From Continuing Ops
Net Income From Continuing Ops	- 0.98	Interest Income
Net Income From Continuing Ops	- 0.98	Net Interest Income
Research Development	- 0.98	Income Before Tax
Research Development	- 0.98	Ebitda